Skip to Main Content
Skip Nav Destination

The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies

Hematology Am Soc Hematol Educ Program (2022) 2022 (1): 603–610.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal